Fingerprinting of Impulsivity

Inclusion criteria

All cohorts:

• Males and females ages 18-50.

Healthy Control cohort:

• Volunteers in generally good Psychiatric and non-Psychiatric medical health

Borderline Personality Disorder (2 cohorts):

• Subjects who meet Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) criteria for Borderline Personality Disorder

Binge Eating Disorder cohort:

• Subjects who meet DSM-V criteria for Binge Eating Disorder.

Stimulant Use Disorder cohort:

• Subjects who meet DSM-V criteria for current Stimulant Use Disorder, subtype cocaine, moderate or severe use

Attention Deficit Hyperactivity Disorder cohort:

• Subjects who meet DSM-V criteria for adult Attention Deficit Hyperactivity Disorder

Exclusion criteria

General:

• Positive breathalyzer test for alcohol at any study visit
• History of clinically significant neurologic disorders or head trauma with loss of consciousness greater than 30 minutes
• Clinically significant non-psychiatric medical disorder requiring ongoing treatment as judged by the investigator.
• Unwillingness or inability to sign a written informed consent form
• Pregnancy as assessed by a urine test for ß-Human Chorionic Gonadotropin (ß-HCG) at screening visit
• Medical or physical contraindications for participation (see below), based on medical history interview, as judged by the investigator
• Unwilling to refrain from tobacco use one hour prior to testing until after conclusion of testing

Healthy Controls:

• Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnoses of Personality Disorders (based on Structured Clinical Interview for DSM-IV (SCID)-II)
• DSM-5 diagnoses based on the SCID-I (including the eating disorders and Attention Deficit Hyperactivity Disorder (ADHD) module)
• History of arrest or incarceration
• Positive urine drug screen for cannabis, cocaine, opioids, amphetamine, and benzodiazepines at any visit
• Current Tobacco Users

Borderline Personality Disorder Subjects:

• DSM-5 diagnoses other than: Tobacco Use Disorder, Major Depressive Disorder (Mild Subtype), Generalized Anxiety Disorder (in remission), Post-Traumatic Stress Disorder (in remission), Major Depressive Disorder (Moderate or Severe Subtype, in remission), or Substance use disorder (Mild subtype, in remission)
• DSM-5 Personality Disorder other than Cluster B Personality disorders.
• Positive urine drug screen for cocaine, opioids, amphetamine, and benzodiazepines at any visit
• Antipsychotic medication or mood stabilizers taken within the last 30 days or change in antidepressant medication within the last 30 days.

Binge Eating Disorder Subjects:

• DSM-5 diagnoses other than: Binge Eating Disorder (current bulimia also excluded), Tobacco Use Disorder, Major Depressive Disorder (in remission), Generalized Anxiety Disorder (in remission), Post-Traumatic Stress Disorder (in remission), and Substance Use Disorder (in remission, mild subtype).
• DSM-5 diagnoses of Cluster B Personality disorders.
• Positive urine drug screen for cocaine, opioids, amphetamine, and benzodiazepines at any visit

Stimulant Use Disorder, Cocaine Subtype Subjects:

• DSM-5 diagnoses other than: Stimulant Use Disorder, Cannabis Use Disorder, Alcohol Use Disorder (Mild Subtype), and Tobacco Use Disorder, Substance Induced Mood Disorder, Major Depressive Disorder (in remission), Generalized Anxiety Disorder (in remission), Post-Traumatic Stress Disorder (in remission).
• DSM-5 diagnoses of Cluster B Personality Disorders.
• Positive urine drug screen for opioids, amphetamine, and benzodiazepines at any visit

ADHD Subjects:

• DSM-5 diagnoses other than ADHD, Substance Induced Mood Disorder, Major Depressive Disorder (in remission), Generalized Anxiety Disorder (in remission), Post-Traumatic Stress Disorder (in remission), Substance Use Disorder (mild subtype, in remission).
• DSM-5 diagnoses of Cluster B Personality Disorders.
• Stimulant medication taken the morning of behavioral testing.
• Positive urine drug screen for cannabis, cocaine, opioids, amphetamine, methamphetamine or benzodiazepines at any visit. Subjects with a valid prescription for amphetamines for the treatment of ADHD will not be excluded.
• Unable or unwilling to withhold medications prescribed for treatment of ADHD on the morning of any behavioral testing clinic visit.
• Further exclusion criteria apply